0R15 8520.0 0.0% 0R1E 8203.0 0.0% 0M69 21090.0 67.5139% 0R2V 226.02 9878.8079% 0QYR None None% 0QYP 412.97 -2.8306% 0RUK 2652.0 -9.2402% 0RYA 1554.0 -0.7029% 0RIH 174.55 -1.3563% 0RIH 165.15 -5.3853% 0R1O 198.5 9800.2494% 0R1O None None% 0QFP None None% 0M2Z 267.777 -0.1763% 0VSO 32.05 -9.9846% 0R1I None None% 0QZI 559.0 0.7207% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 165.7358 2.7149%
Last update at 2024-11-21T16:35:00Z
With 55% ownership, Hikma Pharmaceuticals PLC (LON:HIK) boasts of strong institutional backing
Wed 25 Sep 24, 05:33 AMKLOXXADO® 8mg Naloxone Nasal Spray Shelf-Life Extended from 24 months to 36 months
Thu 15 Aug 24, 07:18 PMWe Think Hikma Pharmaceuticals' (LON:HIK) Robust Earnings Are Conservative
Thu 15 Aug 24, 05:58 AMHikma Pharmaceuticals (HKMPF) Upgraded to Buy: Here's What You Should Know
Mon 12 Aug 24, 04:00 PMHikma Pharmaceuticals PLC Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next
Sun 11 Aug 24, 09:08 AMHikma Pharmaceuticals First Half 2024 Earnings: Beats Expectations
Sat 10 Aug 24, 09:02 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 233.00M | 544.00M | 558.00M | 491.00M | 293.00M |
| Minority interest | -3.00000M | 1.00M | 13.00M | 12.00M | 12.00M |
| Net income | 188.00M | 421.00M | 431.00M | 486.00M | 282.00M |
| Selling general administrative | 509.00M | 488.00M | 464.00M | 494.00M | 246.00M |
| Selling and marketing expenses | - | - | - | 494.00M | 224.00M |
| Gross profit | 1238.00M | 1301.00M | 1201.00M | 1148.00M | 1050.00M |
| Reconciled depreciation | 372.00M | 145.00M | 91.00M | 99.00M | 121.00M |
| Ebit | 507.00M | 582.00M | 579.00M | 493.00M | 331.00M |
| Ebitda | 700.00M | 735.00M | 652.00M | 659.00M | 452.00M |
| Depreciation and amortization | 193.00M | 153.00M | 73.00M | 166.00M | 121.00M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 507.00M | 582.00M | 579.00M | 493.00M | 378.00M |
| Other operating expenses | 2035.00M | 1994.00M | 1827.00M | 1714.00M | 1692.00M |
| Interest expense | 77.00M | 69.00M | 69.00M | 67.00M | 41.00M |
| Tax provision | 42.00M | 124.00M | 128.00M | 4.00M | 8.00M |
| Interest income | 3.00M | 30.00M | 47.00M | 6.00M | 3.00M |
| Net interest income | -52.00000M | -39.00000M | -22.00000M | -1.00000M | -77.00000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 42.00M | 124.00M | 128.00M | 4.00M | 8.00M |
| Total revenue | 2517.00M | 2553.00M | 2341.00M | 2207.00M | 2070.00M |
| Total operating expenses | 756.00M | 742.00M | 687.00M | 655.00M | 672.00M |
| Cost of revenue | 1279.00M | 1252.00M | 1140.00M | 1059.00M | 1020.00M |
| Total other income expense net | -274.00000M | -38.00000M | -21.00000M | -2.00000M | -85.00000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 191.00M | 420.00M | 430.00M | 487.00M | 285.00M |
| Net income applicable to common shares | 188.00M | 421.00M | 431.00M | 486.00M | 282.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-06-30 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | - | 4471.00M | 4372.00M | 4135.00M | 3930.00M |
| Intangible assets | - | 735.00M | 607.00M | 587.00M | 552.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | - | 110.00M | 97.00M | 46.00M | 39.00M |
| Total liab | - | 2323.00M | 1905.00M | 1987.00M | 1801.00M |
| Total stockholder equity | - | 2135.00M | 2453.00M | 2135.00M | 2117.00M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | - | 638.00M | 339.00M | 290.00M | 315.00M |
| Common stock | - | 40.00M | 42.00M | 41.00M | 41.00M |
| Capital stock | - | 40.00M | 42.00M | 41.00M | 41.00M |
| Retained earnings | - | 2092.00M | 2189.00M | 1892.00M | 1973.00M |
| Other liab | - | 111.00M | 164.00M | 195.00M | 223.00M |
| Good will | - | 389.00M | 285.00M | 289.00M | 282.00M |
| Other assets | - | 215.00M | 230.00M | 235.00M | 257.00M |
| Cash | - | 270.00M | 426.00M | 323.00M | 442.00M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | - | 1077.00M | 1016.00M | 1028.00M | 1471.00M |
| Current deferred revenue | - | - | 294.00M | 100.00M | 105.00M |
| Net debt | - | 1013.00M | 420.00M | 609.00M | 243.00M |
| Short term debt | - | 148.00M | 121.00M | 168.00M | 578.00M |
| Short long term debt | - | 139.00M | 112.00M | 158.00M | 569.00M |
| Short long term debt total | - | 1283.00M | 846.00M | 932.00M | 685.00M |
| Other stockholder equity | - | 3.00M | 222.00M | 202.00M | 103.00M |
| Property plant equipment | - | 1081.00M | 1146.00M | 1068.00M | 962.00M |
| Total current assets | - | 1999.00M | 2094.00M | 1922.00M | 1848.00M |
| Long term investments | - | - | - | - | 43.00M |
| Net tangible assets | - | 1011.00M | 1561.00M | 1259.00M | 1283.00M |
| Short term investments | - | 22.00M | 24.00M | 24.00M | 23.00M |
| Net receivables | - | 843.00M | 876.00M | 796.00M | 799.00M |
| Long term debt | - | 1074.00M | 651.00M | 692.00M | 48.00M |
| Inventory | - | 776.00M | 695.00M | 757.00M | 568.00M |
| Accounts payable | - | 291.00M | 262.00M | 470.00M | 473.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | - | -728.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 41.00M | 41.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | -1.00000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | 22.00M | 24.00M | 24.00M | 23.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | - | 2472.00M | 2278.00M | 2213.00M | 2082.00M |
| Capital lease obligations | - | 70.00M | 83.00M | 82.00M | 68.00M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -607.00000M | -238.00000M | -3.00000M | 8.00M | -4.00000M |
| Change to liabilities | 16.00M | 14.00M | 6.00M | -6.00000M | 88.00M |
| Total cashflows from investing activities | -607.00000M | -238.00000M | -283.00000M | -151.00000M | -96.00000M |
| Net borrowings | 447.00M | -114.00000M | 220.00M | -10.00000M | -141.00000M |
| Total cash from financing activities | -58.00000M | -287.00000M | -298.00000M | -155.00000M | -278.00000M |
| Change to operating activities | -49.00000M | 84.00M | 13.00M | -34.00000M | -21.00000M |
| Net income | 233.00M | 544.00M | 558.00M | 491.00M | 282.00M |
| Change in cash | -156.00000M | 103.00M | -119.00000M | 166.00M | 49.00M |
| Begin period cash flow | 426.00M | 323.00M | 442.00M | 276.00M | 227.00M |
| End period cash flow | 270.00M | 426.00M | 323.00M | 442.00M | 276.00M |
| Total cash from operating activities | 530.00M | 638.00M | 464.00M | 472.00M | 430.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 193.00M | 145.00M | 91.00M | 99.00M | 121.00M |
| Other cashflows from investing activities | -3.00000M | -12.00000M | -56.00000M | 33.00M | 48.00M |
| Dividends paid | 125.00M | 120.00M | 109.00M | 97.00M | 84.00M |
| Change to inventory | -102.00000M | 38.00M | -180.00000M | -25.00000M | -51.00000M |
| Change to account receivables | 4.00M | -166.00000M | -47.00000M | 21.00M | -41.00000M |
| Sale purchase of stock | -300.00000M | - | -375.00000M | - | - |
| Other cashflows from financing activities | 1692.00M | 309.00M | -1.00000M | 226.00M | 178.00M |
| Change to netincome | 283.00M | 66.00M | 105.00M | -87.00000M | 64.00M |
| Capital expenditures | 225.00M | 229.00M | 224.00M | 186.00M | 139.00M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -131.00000M | -30.00000M | -208.00000M | -44.00000M | -25.00000M |
| Stock based compensation | 22.00M | 29.00M | 27.00M | 24.00M | 21.00M |
| Other non cash items | 213.00M | 39.00M | 22.00M | 1.00M | 31.00M |
| Free cash flow | 305.00M | 409.00M | 240.00M | 286.00M | 291.00M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (GBP) | Price (GBP) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| HIK Hikma Pharmaceuticals PLC |
27.00 1.46% | 1872.00 | 33.45 | 11.14 | 1.45 | 2.32 | 1.76 | 8.98 |
| HLN Haleon PLC |
3.80 1.03% | 372.40 | 24.73 | 16.86 | 2.63 | 1.81 | 3.17 | 16.57 |
| HCM HUTCHMED China Ltd |
-3.0 1.06% | 281.00 | - | - | 3.22 | 3.97 | 2.39 | -19.4252 |
| INDV Indivior PLC |
10.50 1.27% | 837.00 | - | - | 1.60 | 48.69 | 1.17 | -4.7616 |
| BXP Beximco Pharmaceuticals Limited |
- -% | 33.50 | 5.86 | 4.52 | 0.01 | 0.59 | 0.01 | 0.06 |
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms in North America, the Middle East, North Africa, and Europe. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company was founded in 1978 and is headquartered in London, the United Kingdom.
1 New Burlington Place, London, United Kingdom, W1S 2HR
| Name | Title | Year Born |
|---|---|---|
| Engineer Said Samih Taleb Darwazah | Exec. Chairman & CEO | 1957 |
| Mr. Mazen Samih Taleb Darwazah | Exec. Vice Chairman & Pres of MENA | 1958 |
| Mr. Khalid Waleed Hosny Al Nabilsi | Chief Financial Officer | 1972 |
| Mr. Hussein Arkhagha | Company Sec. & Chief Counsel | NA |
| Mr. Bassam Wael Rushdi Kanaan CFA, CPA | Exec. VP of Corp. Devel. and M&A | 1965 |
| Ms. Susan Ringdal | Exec. VP of Strategic Planning & Global Affairs | NA |
| Ms. Majda Labadi | Exec. VP of Organisational Devel. | NA |
| Mr. Riad Mishlawi | Pres of Injectables | NA |
| Mr. Brian Hoffmann | Pres of Generics | NA |
| Mr. Samuel Park | Global Head of Intellectual Property (IP) & Gen. Counsel for US | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
UK 
AU
CA
US
NZ
Please wait processing your request...